Eyepoint Pharmaceuticals pursues new therapies as anti-VEGF treatments fall short for DME patients

2026-04-08 11:14:42

Eyepoint Pharmaceuticals is advancing its Phase 3 program for diabetic macular edema (DME) to address the limitations of existing anti-VEGF therapies. The company aims to develop more durable treatments that also tackle inflammation, filling a significant gap in current solutions for patients. These efforts are part of Eyepoint’s broader strategy to enhance its market position and product launches, supported by recent leadership appointments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes